Who are the current Executive Committee?
Chair, Fiona McDonald
Fiona is a consultant thoracic oncologist at the Royal Marsden Hospital with over 10 years of SBRT clinical experience. She is the chief investigator for the SARON and HALT trials exploring the role of SBRT in patients with metastatic lung cancer.
Chair-elect, Chris Dean
Chris is the Lead Stereotactic Radiotherapy Physicist for Barts Health NHS Trust in London. His experience commissioning their CyberKnife VSI led to leading this service, enabling delivery of high-quality SABR at Barts since 2011. He initially worked on the SABR Consortium QA sub-group before becoming Consortium Secretary in 2019.
Treasurer, Yat Tsang
Yat is currently employed as a Consultant Radiographer at Mount Vernon Cancer Centre, acting both as a clinical and technical expert leading lead and coordinating the Trust’s specialised radiotherapy (including SABR) service. He initially worked as one of the Consortium executive committee members before becoming the Treasurer in 2019.
QA Lead, Rush Patel
Rushil is the Lead SABR Physicist within the RTTQA group at Mount Vernon Cancer Centre. He has developed QA programmes for the commissioning of SABR/SRS in England in addition to multiple national and international SABR trials. He initially worked as a member of the SABR QA sub-group and has chaired the group since 2018.
Guidelines Lead, Patricia Diez
Patty is a Lead Clinical Scientist for the National RTTQA Group, based at Mount Vernon Cancer Centre. She works on several SABR trials and is currently co-leading the SABR Expansion QA Programme. She joined the SABR Consortium QA sub-group early 2019, before becoming Consortium Guidelines Lead later that year
Who are the rest of the Steering Committee?
Rovel is a Consultant Clinical Oncologist at the Christie in Manchester specialising in stereotactic radiosurgery (SRS), oligometastatic SABR and proton therapy. He trained in SABR and SRS at Yale University and in proton therapy at the University of Florida before returning to the Christie to play a leading role in developing their stereotactic and proton therapy programmes.
Dr Aidan Cole is a Consultant Clinical Oncologist specialising in all aspects of treatment relating to prostate cancer from early disease through to advanced metastatic disease. He is an academic researcher in Queen’s University Belfast dedicated to improving treatments for men with prostate cancer through research and clinical trials.
Lisa is based at the Royal Surrey County Hospital where she is the Operational Manager Radiographer for treatment and stereotactic. Lisa became a member of the SABR Committee in 2021.
Aileen Duffton is Lead Research Radiographer working at the Beatson West of Scotland Cancer Centre, Glasgow, UK. Aileen has a MSc in Advance Practice in Radiotherapy and Oncology (MSc APRO). She is currently a PhD student at University of Glasgow, interested in optimising stereotactic radiotherapy for pancreatic cancer. Aileen is an active member of the ESTRO RTT committee and has led work that increases the profile of advanced practice and research for RTTs.
James is a Consultant Clinical Oncologist at the Queen Elizabeth Hospital in Birmingham, specialising in head/neck and gastro-intestinal cancers. He has a particular interest in SABR for liver and pancreatic cancers, and plays a leading role in a collaborative project with the University of Oxford on the role of MRI-guided SABR.
Helen is the IGRT and Technical Development Lead Physicist at UCLH in London. She was part of the team to commission SABR delivery at UCLH, and now oversees the imaging and motion management aspects of the SABR service. She joined the SABR Consortium QA sub-group in 2017, and became a committee member in 2021.
Dr. Anoop Haridass, is a Consultant Clinical Oncologist and SABR lead at the Clatterbridge cancer center. After completing his fellowship in spinal radiosurgery in Canada, he has help setup a high quality Oligomets SABR service at Clatterbridge. He has been involved in writing the SABR consortium Spinal & Adrenal SABR guidelines and has served as a guidelines group and steering committee member since 2014.
John is the Head of External Beam Radiotherapy Physics for the Leeds Cancer Centre. He has been involved in SABR since 2008 and led the physics aspects of the first UK SABR delivery. He is a former SABR Consortium QA sub-group lead and joined the Committee in 2019.
Rebecca Muirhead initially led the implementation of SABR in Glasgow in 2008 after learning the technique in Amsterdam. She now leads the SABR service in Oxford which treats around 100 patients yearly. She treats primarily lower GI cancer and has a particular interest in SABR reirradiation. She has been involved in the writing of several national guidelines including anal IMRT and rectal IMRT and hopes to bring this experience to SABR guidelines. She is looking forward to using the collaborative nature of the consortium to collect data to further our knowledge and development of SABR.
Dr Clive Peedell is Consultant Clinical Oncologist and clinical lead for Radiotherapy at the James Cook University Hospital, Middlesbrough. He specialises in the management of lung cancer and prostate cancer and has a major interest in the development of the Stereotactic Ablative Body Radiotherapy (SABR/SBRT) services, both locally and nationally. He was a founding member of the UK SABR Consortium and has worked with the All Party Parliamentary Group (APPG) on Radiotherapy to campaign for wider adoption of SABR services in the UK. He is a member of the Steering Committee of the British Thoracic Oncology Group (BTOG).
Dr Thomas Rackley is SABR lead for Velindre Cancer Centre and was responsible for implementing the oligometastatic and HCC SABR services for the population of south Wales. Now as a member of the SABR executive team he is responsible for providing a voice for Wales to ensure SABR developments are in line with NHSE commissioning policies.
Alison is a Consultant Clinical Oncologist at The Royal Marsden hospital, specialising in prostate cancer. Her thesis was on Cyberknife SBRT for prostate and oligometastatic cancers, but she now delivers SBRT on both Elekta linacs and the MR Linac. She leads several SBRT trials including the TRAP trial and is part of the PACE trial team.